KRAS and colorectal carcinoma: Further, treatment with recombinant ephrin-A1-Fc attenuated the unresponsiveness to cetuximab driven by MAPK and AKT activation, in N-Ras mutant and K-Ras wt metastatic CRC cells in vitro [163].